First edition 2012-07-15

Active implantable medical devices — Electromagnetic compatibility — EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices

Dispositifs médicaux implantables actifs — Compatibilité électromagnétique — Protocoles d'essai EMC pour pacemakers cardiaques implantables, défibrillateurs implantables et dispositifs de resynchronisation cardiaque



Reference number ISO 14117:2012(E)



COPYRIGHT PROTECTED DOCUMENT

© ISO 2012

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office Case postale 56 • CH-1211 Geneva 20 Tel. + 41 22 749 01 11 Fax + 41 22 749 09 47 E-mail copyright@iso.org Web www.iso.org

Foreword iv Introduction v 1 Scope 1 2 Normative references 1 3 Terms and definitions, symbols and abbreviations 1 4 Test requirements for the frequency band 0 Hz $\leq f \leq$ 3000 MHz 3 4.1 General 3 4.2 Induced lead current 4 4.3 Protection from sensing EMI as cardiac signals 24 4.4 Temporary response to continuous wave sources 21 4.5 Protection from sensing EMI as cardiac signals 24 4.6 Protection from static magnetic fields of flux density up to 5 mT 34 5.7 Protection from static magnetic fields of flux density up to 50 mT 35 6.8 Protection form AC magnetic field sencountered in a therapeutic environment 41 6 Protection of devices from damage caused by high-frequency surgical exposure 41 6 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2	Contents	Page
Introduction v 1 Scope 1 2 Normative references 1 3 Terms and definitions, symbols and abbreviations 1 4 Test requirements for the frequency band 0 H2 $\leq f \leq 3$ 000 MHz 3 3.1 General 3 4.2 Induced lead current 4 4.3 Protection from sensing EMI as cardiac signals 24 4.6 Protection from sensing EMI as cardiac signals 24 4.7 Protection from sensing EMI as cardiac signals 24 4.8 Protection from sensing EMI as cardiac signals 24 4.7 Protection from static magnetic fields of flux density up to 1 mT 34 4.6 Protection from Static magnetic fields of flux density up to 5 0 mT 35 4.7 Protection of AC magnetic fields of flux density up to 1 40 KHz 36 4.8 Protection of AC magnetic fields of flux density up to 1 40 KHz 36 4.9 Testing above frequency of 3 000 MHz 41 6 Protection of the device from damage caused by high-frequency zurgical exposure 41 6.1 Disclosure of permanenty programmable sensitivity settings 6	Foreword	iv
1 Scope 1 2 Normative references 1 3 Terms and definitions, symbols and abbreviations 1 4 Test requirements for the frequency band 0 Hz $\leq f \leq 3$ 000 MHz 3 4.1 General 3 4.2 Induced lead current 4 4.3 Protection from persisting malfunction attributable to ambient electromagnetic fields 11 4.4 Test requirements for the frequency sources 21 4.5 Protection from sensing EMI as cardiac signals 24 4.6 Protection from static magnetic fields of flux density up to 50 mT 35 4.3 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq 3$ 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of the device from damage caused by high-frequency surgical exposure 41 6.1 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.3 Known potential hazardous behaviour 46 7.4 </td <td>Introduction</td> <td>v</td>	Introduction	v
2 Normative references 1 3 Terms and definitions, symbols and abbreviations 1 4 Test requirements for the frequency band 0 Hz $\leq f \leq 3$ 000 MHz 3 4.1 General 3 4.2 Induced lead current. 4 4.3 Protection from persisting malfunction attributable to ambient electromagnetic fields 11 4.4 Temporary response to continuous wave sources 21 4.5 Protection from sensing EMI as cardiac signals 24 4.6 Protection from static magnetic fields of flux density up to 5 0 mT 35 4.8 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq 3$ 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by high-frequency surgical exposure 42 7 Additional accompanying documentation 46 7.3 Known potential hazardous behaviour 46 7.4 Additional accompanying documentation	1 Scope	1
3 Terms and definitions, symbols and abbreviations 1 4 Test requirements for the frequency band 0 Hz $\leq f \leq$ 3 000 MHz 3 4.1 General 3 4.2 Induced lead current. 4 4.3 Protection from persisting malfunction attributable to ambient electromagnetic fields. 11 4.4 Temporary response to continuous wave sources. 21 1.5 Protection from sensing EMI as cardiac signals. 24 4.6 Protection from static magnetic fields of flux density up to 1 mT 34 4.7 Protection from AC magnetic field soposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq$ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of the device from damage caused by high-frequency surgical exposure 41 6.1 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of peramanetity programmable sensitivity settings 46 7.2 Descriptions of reversion modes. 46 7.3 Known potentia	2 Normative references	1
4 Test requirements for the frequency band 0 Hz $\leq f \leq$ 3 000 MHz 3 4.1 General 3 4.2 Induced lead current. 4 4.3 Protection from persisting malfunction attributable to ambient electromagnetic fields. 11 4.4 Temporary response to continuous wave sources. 21 1.5 Protection from sensing EMI as cardiac signals. 24 4.6 Protection from static magnetic fields of flux density up to 1 mT 34 4.7 Protection from AC magnetic field sposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq$ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of the device from damage caused by high-frequency surgical exposure 41 6.1 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes. 46 7.3 Known potential hazardous behaviour 46 7.4 Destriptions of reversion m	3 Terms and definitions, symbols and abbreviations	1
4.1 General 3 4.2 Induced lead current. 4 4.3 Protection from persisting malfunction attributable to ambient electromagnetic fields. 11 4.4 Temporary response to continuous wave sources. 21 4.5 Protection from sensing EMI as cardiac signals. 24 4.6 Protection from static magnetic fields of flux density up to 1 mT. 34 4.7 Protection from C magnetic field sopsure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz ≤ f ≤ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz. 41 6 Protection of devices from EM fields encountered in a therapeutic environment. 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure. 41 6.2 Protection of the device from damage caused by external defibrillators. 42 7 Additional accompanying documentation. 46 7.3 Known potential hazardous behaviou. 46 7.4 Informative) Rationale 47 Annex A (informative) Rationale for test frequency ranges. 58 Annex D (normative) Note of expacitor C _x . <	4 Test requirements for the frequency band 0 Hz $\leq f \leq$ 3 000 MHz	3
1.3 Protection from persisting malfunction attributable to ambient electromagnetic fields. 11 1.4 Temporary response to continuous wave sources. 21 1.5 Protection from sensing EMI as cardiac signals. 24 4.6 Protection from static magnetic fields of flux density up to 1 mT. 34 4.7 Protection from AC magnetic fields of flux density up to 50 mT. 35 4.8 Protection from AC magnetic fields of flux density up to 50 mT. 35 5 Testing above frequency of 3 000 MHz. 41 6 Protection of devices from EM fields encountered in a therapeutic environment. 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure. 41 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings. 46 7.2 Descriptions of reversion modes. 47 7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale for test frequency ranges. 58 Annex D (normative) Interface circuits. 65 Annex E (informative) Selection of capacitor C _x . 70 Annex E (informative) Selection of the injecti	4.1 General	
4.4 Temporary response to continuous wave sources 21 4.5 Protection from sensing EMI as cardiac signals 24 4.6 Protection from static magnetic fields of flux density up to 1 mT 34 4.7 Protection from static magnetic fields of flux density up to 50 mT 35 4.8 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz ≤ f ≤ 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.1 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes 46 7.3 Known potential hazardous behaviour 46 7.4 Annex A (informative) Rationale for test frequency ranges 58 7.4 Annex D (normative) Rationale for test frequency ranges 58 7.4 Annex D (normative) Code for describing modes of impl	4.3 Protection from persisting malfunction attributable to ambient electromagnetic field	ds11
4.5 Protection from sensing EMI as cardiac signals 24 4.6 Protection from static magnetic fields of flux density up to 1 mT 34 4.7 Protection from static magnetic fields of flux density up to 50 mT 35 4.8 Protection from AC magnetic fields of flux density up to 50 mT 35 4.9 Test requirements for the frequency range of 450 MHz ≤ f ≤ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes. 46 7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale for test frequency ranges. 58 Annex D (normative) Rationale for test frequency ranges. 58 Annex D (normative) Selection of capacitor C _x . 70 Annex F (normative) Selection	4.4 Temporary response to continuous wave sources	
4.7 Protection from static magnetic fields of flux density up to 50 mT 35 4.8 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq$ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes. 46 7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale 47 47 Annex B (informative) Rationale for test frequency ranges. 58 Annex C (informative) Selection of capacitor C _x . 70 Annex F (normative) Selection of the injection network (Figure D.5). 71 Annex G (normative) Dipole antennas. 76 Annex I (normative) Dipole antennas. 76	4.5 Protection from sensing EMI as cardiac signals	
4.8 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz 36 4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq$ 3 000 MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment. 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes. 46 7.3 Known potential hazardous behaviour 46 Annex A (informative) Rationale 47 47 Annex B (informative) Rationale for test frequency ranges. 58 Annex D (normative) Interface circuits. 65 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex I (normative) Simulated cardiac signal. 80 Annex K	4.6 Protection from static magnetic fields of flux density up to 50 mT	
4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq 3000$ MHz 37 5 Testing above frequency of 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes 46 7.3 Known potential hazardous behaviour 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges 58 Annex D (normative) Interface circuits 65 65 Annex E (informative) Selection of capacitor C_x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Torso simulator 73 Annex I (normative) Dipole antennas 76 Annex I (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex K (normative) Correlation between levels of test v	4.8 Protection from AC magnetic field exposure in the range of 1 kHz to 140 kHz	
5 Testing above frequency of 3 000 MHz 41 6 Protection of devices from EM fields encountered in a therapeutic environment 41 6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes 46 7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges 58 Annex C (informative) Code for describing modes of implantable generators 63 Annex E (informative) Selection of capacitor C _x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Dipole antennas 76 Annex I (normative) Dipole antennas 76 Annex I (normative) Simulated cardiac signal 80 Annex K (normative) Colculation of net power into dipole antenna 81 Annex K (normative) Correlation between levels of test voltages used in this Internat	4.9 Test requirements for the frequency range of 450 MHz $\leq f \leq$ 3 000 MHz	
6 Protection of devices from EM fields encountered in a therapeutic environment	5 Testing above frequency of 3 000 MHz	
6.1 Protection of the device from damage caused by high-frequency surgical exposure 41 6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes 46 7.3 Known potential hazardous behaviour 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges 58 Annex C (informative) Code for describing modes of implantable generators 63 Annex D (normative) Interface circuits 65 Annex F (normative) Selection of capacitor C _x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Dipole antennas 76 Annex I (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex K (normative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields <td>6 Protection of devices from EM fields encountered in a therapeutic environment</td> <td></td>	6 Protection of devices from EM fields encountered in a therapeutic environment	
6.2 Protection of the device from damage caused by external defibrillators 42 7 Additional accompanying documentation 46 7.1 Disclosure of permanently programmable sensitivity settings 46 7.2 Descriptions of reversion modes 46 7.3 Known potential hazardous behaviour 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges 58 Annex C (informative) Code for describing modes of implantable generators 63 Annex D (normative) Interface circuits 65 Annex F (normative) Selection of capacitor C _x 70 Annex G (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Dipole antennas 76 Annex I (normative) Dipole antennas 76 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	6.1 Protection of the device from damage caused by high-frequency surgical exposure	9
7 Additional accompanying documentation. 46 7.1 Disclosure of permanently programmable sensitivity settings. 46 7.2 Descriptions of reversion modes. 46 7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges. 58 Annex C (informative) Code for describing modes of implantable generators. 63 Annex D (normative) Interface circuits. 65 Annex F (informative) Selection of capacitor C _x . 70 Annex F (normative) Calibration of the injection network (Figure D.5). 71 Annex G (normative) Dipole antennas 76 Annex I (normative) Dipole antennas 76 Annex J (normative) Simulated cardiac signal. 80 Annex K (normative) Calculation of net power into dipole antenna. 81 Annex L (informative) Loop area calculations. 85 Annex M (informative) Loop area calculations. 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields. 90 Bibliography 96	6.2 Protection of the device from damage caused by external defibrillators	
7.1 Disclosure of permanently programmable sensitivity settings	7 Additional accompanying documentation	
7.3 Known potential hazardous behaviour. 46 Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges. 58 Annex C (informative) Code for describing modes of implantable generators. 63 Annex D (normative) Interface circuits. 65 Annex F (informative) Selection of capacitor C _x . 70 Annex F (normative) Calibration of the injection network (Figure D.5). 71 Annex G (normative) Torso simulator. 73 Annex H (normative) Dipole antennas. 76 Annex J (normative) Simulated cardiac signal. 80 Annex K (normative) Calculation of net power into dipole antenna. 81 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields. 90 Bibliography 96	7.1 Disclosure of permanently programmable sensitivity settings	
Annex A (informative) Rationale 47 Annex B (informative) Rationale for test frequency ranges 58 Annex C (informative) Code for describing modes of implantable generators 63 Annex D (normative) Interface circuits 65 Annex E (informative) Selection of capacitor C _x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Torso simulator 73 Annex H (normative) Dipole antennas 76 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	7.3 Known potential hazardous behaviour.	
Annex B (informative) Rationale for test frequency ranges 58 Annex C (informative) Code for describing modes of implantable generators 63 Annex D (normative) Interface circuits 65 Annex E (informative) Selection of capacitor C _x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Torso simulator 73 Annex H (normative) Dipole antennas 76 Annex I (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex A (informative) Rationale	
Annex C (informative) Code for describing modes of implantable generators 63 Annex D (normative) Interface circuits 65 Annex E (informative) Selection of capacitor C _x 70 Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Torso simulator 73 Annex H (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex K (normative) Calculation of net power into dipole antenna 80 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex B (informative) Rationale for test frequency ranges	
Annex D (normative) Interface circuits. 65 Annex E (informative) Selection of capacitor C _x . 70 Annex F (normative) Calibration of the injection network (Figure D.5). 71 Annex G (normative) Torso simulator. 73 Annex H (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex J (normative) Simulated cardiac signal. 80 Annex K (normative) Calculation of net power into dipole antenna. 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex C (informative) Code for describing modes of implantable generators	
Annex E (informative) Selection of capacitor C _x	Annex D (normative) Interface circuits	
Annex F (normative) Calibration of the injection network (Figure D.5) 71 Annex G (normative) Torso simulator 73 Annex H (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex E (informative) Selection of capacitor C _x	
Annex G (normative) Torso simulator 73 Annex H (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex F (normative) Calibration of the injection network (Figure D.5)	
Annex H (normative) Dipole antennas 76 Annex I (normative) Pacemaker/ICD programming settings 78 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex G (normative) Torso simulator	
Annex I (normative) Pacemaker/ICD programming settings 78 Annex J (normative) Simulated cardiac signal 80 Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex H (normative) Dipole antennas	
Annex J (normative) Simulated cardiac signal	Annex I (normative) Pacemaker/ICD programming settings	
Annex K (normative) Calculation of net power into dipole antenna 81 Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex J (normative) Simulated cardiac signal	
Annex L (informative) Loop area calculations 85 Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography 96	Annex K (normative) Calculation of net power into dipole antenna	
Annex M (informative) Correlation between levels of test voltages used in this International Standard and strengths of radiated fields 90 Bibliography	Annex L (informative) Loop area calculations	
Bibliography	Annex M (informative) Correlation between levels of test voltages used in this International and strengths of radiated fields	Standard 90
	Bibliography	

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 14117 was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 6, *Active implants*.

ISO 14117 is based on ANSI/AAMI PC69:2007. The relationship between the documents is addressed in A.2.4.

Introduction

The number and the types of electromagnetic (EM) emitters to which patients with active implantable cardiovascular devices are exposed in their day-to-day activities have proliferated over the past two decades. This trend is expected to continue. The interaction between these emitters and active implantable cardiovascular devices (pacemakers and implantable cardioverter defibrillators, or ICDs) is an ongoing concern of patients, industry and regulators, given the potential life-sustaining nature of these devices. The risks associated with such interactions include device inhibition or delivery of inappropriate therapy that, in the worst case, could result in serious injury or patient death.

In recent years, other active implantable cardiovascular devices have emerged, most notably devices that perform the function of improving cardiac output by optimizing ventricular synchrony, in addition to performing pacemaker or ICD function.

Although these devices can deliver an additional therapy with respect to pacemakers and ICD devices, most of their requirements concerning EM compatibility are similar so that, in most cases, the concepts that apply to pacemakers also apply to CRT-P devices, and the appropriate way to test a CRT-P device is similar to the way pacemakers are tested. Similarly, the concepts that apply to ICD devices mostly apply to CRT-D devices as well, so the appropriate way to test a CRT-D device is similar to the way ICD devices are tested.

Standard test methodologies allow manufacturers to evaluate the EM compatibility performance of a product and demonstrate that the product achieves an appropriate level of EM compatibility in uncontrolled EM environments that patients may encounter.

It is important that manufacturers of transmitters and any other equipment that produces EM fields (intentional or unintentional) understand that such equipment may interfere with the proper operation of active implantable cardiovascular devices.

It is important to understand that these interactions may occur despite the conformance of the device to this International Standard and the conformance of emitters to the relevant human exposure safety standards and pertinent regulatory emission requirements, e.g. those of the U.S. Federal Communications Commission (FCC).

Compliance with biological safety guidelines does not necessarily guarantee EM compatibility with active implantable cardiovascular devices. In some cases, the reasonably achievable EM immunity performance for these devices falls below these biological safety limits.

The potential for emitter equipment to interfere with active implantable cardiovascular devices is complex and depends on the following factors:

- frequency content of the emitter,
- modulation format,
- power of the signal,
- proximity to the patient,
- coupling factors, and
- duration of exposure.

Devices within the scope of this International Standard are life-sustaining and are designed to sense low-level physiological signals (as low as 0,1 mV) that have frequency content up to several hundred Hertz. For patient safety and comfort, these devices are small, offer many therapeutic features, and have a long battery life. These highly desired features, combined with the intrinsic functionality, limit the size and number of components and thus place practical constraints on the capability to control electromagnetic interference (EMI).

An emitter with a fundamental carrier frequency up to several hundred Hertz has the potential to be sensed directly by the pacemaker or ICD. Also, higher-frequency carriers that are modulated up to several hundred Hertz and that have sufficient proximity and power may be sensed by the pacemaker or ICD.

Additional details regarding this issue can be found in Annex M.

This International Standard addresses the EM compatibility of pacemakers and ICDs up to 3 000 MHz and is divided in several sections.

a) $0 \text{ Hz} \le f < 450 \text{ MHz}$

In the lower-frequency bands (<450 MHz), there are many EM emitters, such as broadcast radio and television, and a number of new technologies or novel applications of established technologies that may increase the likelihood of interaction between the emitters and patients' pacemakers and ICDs. A few examples:

- electronic article surveillance (EAS) systems;
- access control systems (radio-frequency identification, or RFID);
- new wireless service in the ultra-high-frequency and very-high-frequency bands;
- magnetic levitation rail systems;
- radio-frequency (RF) medical procedures, such as high-frequency surgery and ablation therapy;
- metal detectors;
- magnetic resonance imaging; and
- experimental use of transponders for traffic control.
- b) 450 MHz $\leq f < 3000$ MHz

These are the frequencies, *f*, that are typically associated with personal hand-held communication devices (e.g. wireless telephones and two-way radios).

Two decades ago, relatively few pacemaker patients used hand-held transmitters or were exposed to EM fields from portable transmitters. Hand-held, frequency-modulated transceivers for business, public safety, and amateur radio communications represented the predominant applications. However, the environment has changed rapidly during the past 15 years, with wireless phone systems becoming increasingly common as this technology matured and received widespread public acceptance. Thus, it is becoming increasingly likely that a large portion of the pacemaker and ICD patient population will be exposed to EM fields from portable wireless phone transmitters operated either by themselves or by others. Also, it should be expected that the wireless technology revolution will continue to evolve new applications using increasingly higher microwave frequencies.

Most electronic equipment, including external medical devices, has been designed for compatibility with relatively low-amplitude EM conditions. Recognizing the wide range of EM environments that patients could encounter, implantable devices have been designed to tolerate much higher-amplitude EM conditions than most other electronic products. However, in some instances, even this enhanced immunity is not sufficient to achieve compatibility with the complex electric and magnetic fields generated by low-power emitters located within a few centimetres of the implantable device. Studies in the mid-1990s demonstrated that some models of pacemakers and ICDs had insufficient immunity to allow unrestricted use when in close proximity to some hand-held emitters (e.g. wireless telephones and two-way radios). Although operating restrictions can help prevent EM interaction with implantable devices, this approach is not viewed as an optimum long-term solution. Rather, improved EM compatibility is the preferred method for meeting patient expectations for using wireless services with minimal operating restrictions.

Some technological factors are contributing to the expanding variety of emitters to which patients may now be exposed:

- smaller wireless phones,
- the introduction of digital technology, and
- peak transmitter power.

Wireless phone size has now been reduced sufficiently so that it is possible for patients to carry a phone that is communicating or in standby mode in a breast pocket immediately adjacent to a pectorally implanted device.

Since 1994, reported studies have indicated that interference effects in pacemakers are more severe from digital phones than from analog phones. As of September 2010, there were more than 5 billion digital subscriptions worldwide.

The various wireless phone standards allow for a range of power levels and modulation schemes. Most digital wireless phones are capable of producing greater peak transmitted power than analog phones are capable of producing. Those factors contribute to greater potential interactions with pacemakers and ICDs.

For frequencies of 450 MHz $\leq f \leq$ 3 000 MHz, this International Standard specifies testing at 120 mW net power into a dipole antenna to simulate a hand-held wireless transmitter 15 cm from the implant. An optional characterization test is described that uses higher power levels to simulate a hand-held wireless transmitter placed much closer to the implant. Claims that the manufacturer may wish to make on the basis of the results of the optional characterization are to be negotiated between the manufacturer and the appropriate regulatory authorities.

c) $f \ge 3,000 \text{ MHz}$

This International Standard does not require testing of devices above 3 GHz. The upper-frequency limit chosen for this International Standard reflects consideration of the following factors:

- 1) the types of radiators of frequencies above 3 GHz,
- 2) the increased device protection afforded by the attenuation of the enclosure and body tissue at microwave frequencies,
- 3) the expected performance of EMI control features that typically are implemented to meet the lowerfrequency requirements of this International Standard, and
- 4) the reduced sensitivity of circuits at microwave frequencies.

Additional details can be found in Clause 5.

In conclusion, it is reasonable to expect that patients with pacemakers and ICDs will be exposed to increasingly complex EM environments. Also, the rapid evolution of new technologies and their acceptance by patients will lead to growing expectations for unrestricted use. In view of the changing EM environment and customer expectations, manufacturers will need to evaluate their product designs to assess compatibility with the complex fields, broad range of frequencies, and variety of modulation schemes associated with existing and future applications.